Novo enters RNAi via liver disease deal with Dicerna

As Novo continues to remake its R&D, it is adding RNAi technology to its toolkit though a liver-focused deal with Dicerna.

The partners will use Dicerna's GalXC platform to explore more than 30

Read the full 332 word article

User Sign In